News | April 03, 2015

German University Reports First Radiotherapy Patient Treatments on Integrated Brainlab/Elekta System

Setup combines Brainlab’s ExacTrac patient positioning system with Elekta Versa HD linear accelerator

Brainlab, ExacTrac, Versa HD, Elekta, LMU, Munich, LINAC, first

Ludwig Maximilian University Hospital has integrated Elekta's Versa HD linear accelerator system with Brainlab's ExacTrac patient positioning system, pictured here.

April 3, 2015 — Brainlab announced first patient treatments on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.  

By streamlining treatment workflow, ExacTrac and Versa HD increase patient positioning efficiency and provide highly accurate solutions for frameless stereotactic radiosurgery (SRS) and stereotactic body radiotherapy treatment (SBRT). The accuracy is further enriched with the ability to detect and manage intra-fractional patient motion during treatment delivery.

The integrated ExacTrac/Versa HD solution is currently in routine clinical use at Ludwig-Maximilian University Hospital in Munich. To date, the hospital has treated 12 patients with a range of indications and has plans to expand their ExacTrac/Versa HD program.

“The LMU Medical Center prides itself on offering advanced technology and finding new ways to optimize our existing infrastructure. Combining these innovative cancer treatment technologies – Brainlab ExacTrac and Elekta Versa HD – allows us to maximize the benefits of both systems for our patients, including intra-fractional verification,” said Prof. Claus Belka, medical director of radiotherapy and radiation oncology at LMU Medical Center, Grosshadern and Innenstadt clinics and polyclinics. “The integrated solution allows us to perform SRS and SBRT cases with submillimetric accuracy and the seamless workflow has allowed us to provide comfortable and fast treatment for patients.”

ExacTrac and Versa HD enable treatment of conventional as well as complex cancers that require highly accurate targeting precision expanding the reach and richness of SRS and SBRT for facilities looking to leverage resources and deliver advanced, sophisticated therapies across several different LINACs.

ExacTrac is used to perform precise patient positioning and monitoring in the treatment of tumors in the brain and body. ExacTrac offers sub-millimetric positioning precision and can be used with a non-invasive stereotactic mask system. 

For more information: www.brainlab.com

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Overlay Init